First National Bank of Omaha Sells 406 Shares of Integer Holdings Co. (NYSE:ITGR)

First National Bank of Omaha reduced its holdings in shares of Integer Holdings Co. (NYSE:ITGR) by 1.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,321 shares of the medical equipment provider’s stock after selling 406 shares during the period. First National Bank of Omaha’s holdings in Integer were worth $3,032,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Driehaus Capital Management LLC increased its holdings in shares of Integer by 62.5% during the second quarter. Driehaus Capital Management LLC now owns 353,052 shares of the medical equipment provider’s stock valued at $40,880,000 after acquiring an additional 135,750 shares in the last quarter. Eagle Asset Management Inc. purchased a new stake in Integer during the 3rd quarter valued at about $14,403,000. F M Investments LLC bought a new stake in Integer during the 2nd quarter valued at about $11,143,000. Point72 Europe London LLP purchased a new position in Integer in the second quarter worth about $6,241,000. Finally, Bamco Inc. NY lifted its stake in shares of Integer by 17.4% in the third quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider’s stock worth $33,069,000 after buying an additional 37,700 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Trading Up 0.1 %

Integer stock opened at $139.39 on Monday. Integer Holdings Co. has a 52-week low of $86.42 and a 52-week high of $142.76. The company has a market cap of $4.68 billion, a P/E ratio of 43.02, a P/E/G ratio of 2.02 and a beta of 1.12. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The business has a 50-day simple moving average of $132.63 and a two-hundred day simple moving average of $125.17.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.07. The company had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.27 earnings per share. Analysts predict that Integer Holdings Co. will post 5.33 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ITGR shares. Bank of America boosted their price objective on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Benchmark boosted their price target on Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Wells Fargo & Company reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Integer in a research report on Tuesday, December 3rd. Citigroup boosted their target price on Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $140.00 price target (up previously from $125.00) on shares of Integer in a report on Friday, October 25th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $142.00.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.